Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors

Ripretinib is a safe and an effective therapy for the fourth-line setting in advanced/metastatic GIST. Future studies should evaluate combination schedules and the identification of markers predictive of benefit from ripretinib.